#None #cancer therapies #stock offering #Intensity Therapeutics

Intensity Therapeutics Secures $4 Million from Direct Stock Offering

Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical biotechnology firm dedicated to creating innovative intratumoral cancer therapies, recently announced the successful pricing of a registered direct offering, raising approximately $4 million. This offering involves the sale of 5 million shares of common stock at a price of $0.80 per share. The proceeds from the offering are strategically intended for the continuation of clinical trials, covering general corporate expenses, and boosting working capital.

The Offering Details

The securities purchase agreement involves a long-term investor, highlighting confidence in Intensity's innovative approaches to cancer treatment. The completion of this offering is anticipated by November 3, 2025, based on the fulfillment of customary closing conditions. This financial influx is expected to extend Intensity's cash runway into the first quarter of 2027, providing essential funds to advance its clinical efforts.

Innovative Approach to Cancer Treatment

Intensity Therapeutics is recognized for its proprietary non-covalent conjugation technology, which enhances the delivery of cytotoxic drugs directly into tumors. This method not only aids in tumor destruction but also enhances the immune system's ability to recognize and fight cancer cells. With the company's flagship treatment, INT230-6, early clinical trials have demonstrated promising results, evidencing the drug's capability to kill tumor cells and spark an immune response shortly after administration.

The firm has conducted successful trials, enrolling over 200 patients, focusing primarily on metastatic cancers, including sarcomas and breast cancer. The results from these trials show not just potential effectiveness but also a new approach towards shifting how certain cancers are treated, potentially transforming them into manageable chronic conditions.

Clinical Trials and Future Directions

Currently, the company is advancing multiple clinical trials:

• - Phase 1/2 Study: Focusing on metastatic cancers like sarcomas (NCT03058289).
• - INVINCIBLE-2 Study: A Phase 2 clinical trial addressing locally advanced breast cancer in women prior to surgical interventions (NCT04781725).
• - INVINCIBLE-3 Study: Aiming to test INT230-6 as a monotherapy in soft tissue sarcoma patients compared to standard care, with overall survival as a key endpoint (NCT06263231).
• - INVINCIBLE-4 Study: Partnering with The Swiss Group for Clinical Cancer Research to assess the effectiveness of INT230-6 in conjunction with standard immunochemotherapy for patients with presurgical triple-negative breast cancer (NCT06358573).

As these studies progress, results are eagerly awaited that could provide significant insights into how this innovative therapy can redefine cancer treatments and patient outcomes.

Cautionary Note

As with any forward-looking statements, management emphasizes that while expectations are based on current projections, actual results can diverge due to various uncertainties and risks inherent in the biotech landscape. Investors are urged to consider these elements carefully, as outlined in the company's filings with the SEC.

Conclusion

With the recent direct offering and ongoing clinical trials, Intensity Therapeutics is poised to make impactful advances in the field of cancer treatment. The commitment to innovation and patient outcomes highlights the company’s mission to transform the landscape of cancer therapies, potentially changing the lives of many individuals facing these challenges. For more detailed information, visit Intensity Therapeutics.